SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2024 operating results on Wednesday, February 26, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
Conference Call Details
The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID “HCATQ424.” A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Health Catalyst
Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst’s offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.
Health Catalyst Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855) 309-6800
ir@healthcatalyst.com
Health Catalyst Media Contact:
Amanda Flanders
Senior Vice President, Marketing and Communications
media@healthcatalyst.com
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the…
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic…
Annamycin delivering better performance 7th line than would be expected even in 2nd line for…
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation…
Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral…
LOS ANGELES, June 04, 2025 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Expert Market: VDRM), a…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
